Controversy Continues Over Muscular Dystrophy Drug, Despite FDA Approval

Email a Friend
The Food and Drug Administration approved a muscular dystrophy drug despite deeply flawed evidence. Was the decision a dangerous precedent or flexible pragmatism reflecting patients' values?